Accessibility Menu
 
Nektar Therapeutics logo

Nektar Therapeutics

(NASDAQ) NKTR

Current Price$81.86
Market Cap$2.72B
Since IPO (1994)+46%
5 Year-73%
1 Year+782%
1 Month+9%

Nektar Therapeutics Financials at a Glance

Market Cap

$2.72B

Revenue (TTM)

$55.63M

Net Income (TTM)

$158.10M

EPS (TTM)

$-8.42

P/E Ratio

-9.73

Dividend

$0.00

Beta (Volatility)

1.74 (High)

Price

$81.86

Volume

38,843

Open

$84.00

Previous Close

$81.86

Daily Range

$80.97 - $84.00

52-Week Range

$7.99 - $109.00

NKTR: Motley Fool Moneyball Superscore

45

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Nektar Therapeutics

Industry

Pharmaceuticals

Employees

63

CEO

Howard W. Robin

Headquarters

San Francisco, CA 94158, US

NKTR Financials

Key Financial Metrics (TTM)

Gross Margin

80%

Operating Margin

-2%

Net Income Margin

-3%

Return on Equity

-54%

Return on Capital

-18%

Return on Assets

-21%

Earnings Yield

-10.28%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.72B

Shares Outstanding

33.21M

Volume

38.84K

Avg. Volume

1.27M

Financials (TTM)

Gross Profit

$55.23M

Operating Income

$130.77M

EBITDA

$129.74M

Operating Cash Flow

$208.51M

Capital Expenditure

$171.00K

Free Cash Flow

$208.68M

Cash & ST Invst.

$245.75M

Total Debt

$148.91M

Nektar Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$10.86M

+3.8%

Gross Profit

$0.00

-100.0%

Gross Margin

0.00%

N/A

Market Cap

$2.72B

N/A

Market Cap/Employee

$44.59M

N/A

Employees

61

N/A

Net Income

$44.90M

+11.7%

EBITDA

$39.05M

+4.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Net Cash

$485.44M

+310.4%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$60.63M

-22.8%

Short Term Debt

$22.53M

+3.2%

Return on Assets

-20.71%

N/A

Return on Invested Capital

-17.84%

N/A

Free Cash Flow

$0.00

+100.0%

Operating Cash Flow

$0.00

+100.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ELVNEnliven Therapeutics, Inc.
$40.75+1.14%
RLAYRelay Therapeutics, Inc.
$12.76+2.00%
INBXInhibrx Biosciences, Inc.
$134.35+7.89%
SNDXSyndax Pharmaceuticals, Inc.
$21.49+4.63%

Trending Stocks

Symbol / CompanyPricePrice Chg
RXTRackspace Technology
$5.49+0.56%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$15.62+0.08%
NOKNokia
$12.82+0.04%
POETPoet Technologies
$10.95+0.14%

Questions About NKTR

What is the current price of Nektar Therapeutics?

Nektar Therapeutics is trading at $81.86 per share.

What is the 52-week range for Nektar Therapeutics?

Over the past 52 weeks, Nektar Therapeutics has traded between $7.99 and $109.00.

How much debt does Nektar Therapeutics have?

As of the most recent reporting period, Nektar Therapeutics reported total debt of $143.43M.

How much cash does Nektar Therapeutics have on hand?

Nektar Therapeutics reported $131.87M in cash and cash equivalents in its most recent financial results.

What is Nektar Therapeutics’s dividend yield?

Nektar Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.